Drug updated on 4/17/2024
| Dosage Form | Tablet (oral; 50 mg, 100 mg, 200 mg) |
| Drug Class | Phosphodiesterase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of erectile dysfunction.
Summary
- Avanafil (Stendra) is indicated for the treatment of erectile dysfunction and has been shown to improve metrics such as the International Index of Erectile Function - Erectile Function scores and Sexual Encounter Profile responses, particularly at a 200 mg dosage.
- The information was derived from seven systematic reviews/meta-analyses on avanafil's efficacy, safety profile, and considerations for population types and subgroups in treating erectile dysfunction.
- Treatment-Emergent Adverse Events were higher in groups treated with avanafil compared to placebo. However, there were no significant differences between the 100 mg and 200 mg dosages, suggesting that while adverse effects increase with the use of avanafil, they do not proportionally increase with a higher dosage within this range.
- In comparison to other phosphodiesterase type 5 inhibitors (PDE5Is), some drugs showed lower effectiveness or higher rates of adverse events than avanafil. This suggests that low-dose sildenafil or tadalafil may be safer or more effective alternatives for certain populations.
- Among men suffering from post-operative ED following pelvic surgeries like radical prostatectomy, avanafil, along with other PDE5Is, improved erectile function, but further randomized controlled trials are needed to determine superiority among these medications specifically in managing post-surgery ED cases.
- A study on gene polymorphisms' possible involvement in response to PDE5Is highlighted an association, especially concerning endothelial nitric oxide synthase polymorphism, indicating potential future personalized medicine approaches towards ED treatment using drugs like avanafil.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Stendra (avanafil) Prescribing Information. | 2022 | Metuchen Pharmaceuticals LLC, Freehold, NJ |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Pharmacological treatment and inappropriate prescriptions for patients with erectile dysfunction. | 2020 | International Journal of Clinical Pharmacy |
| Practical guidelines for the treatment of erectile dysfunction and Peyronie’s disease. | 2020 | Urologic Principles and Practice |
| Current diagnosis and management of erectile dysfunction. | 2019 | Australian Centre for Sexual Health, Sydney, NSW |